Which of the following is false about pioglifazone?
**Core Concept**
Pioglitazone is a thiazolidinedione (TZD) medication used in the treatment of type 2 diabetes mellitus. It works by activating the peroxisome proliferator-activated receptor-gamma (PPAR-γ), which regulates glucose metabolism and insulin sensitivity.
**Why the Correct Answer is Right**
Pioglitazone increases insulin sensitivity by enhancing the transcription of genes involved in glucose uptake and storage. It also decreases hepatic glucose production by inhibiting the expression of key enzymes involved in gluconeogenesis. Additionally, pioglitazone has anti-inflammatory and anti-fibrotic effects, which contribute to its therapeutic benefits in patients with type 2 diabetes.
**Why Each Wrong Option is Incorrect**
**Option A:** Pioglitazone is not a sulfonylurea, but rather a thiazolidinedione (TZD) that works by activating PPAR-γ. It does not stimulate insulin release from the pancreatic beta cells.
**Option B:** Pioglitazone does not cause a significant increase in heart rate or blood pressure. In fact, it may have a neutral or even negative effect on cardiovascular risk factors due to its anti-inflammatory and anti-fibrotic effects.
**Option C:** Pioglitazone can cause fluid retention, but this is not a primary mechanism of action. It is more closely related to the drug's effect on sodium retention in the kidneys.
**Clinical Pearl / High-Yield Fact**
Pioglitazone should be used with caution in patients with heart failure, as it may exacerbate fluid overload and worsening of cardiac function. It is essential to monitor patients for signs of fluid retention and adjust the dosage or discontinue the medication if necessary.
**Correct Answer: C. Pioglitazone can cause fluid retention, but this is not a primary mechanism of action. It is more closely related to the drug's effect on sodium retention in the kidneys.**